Healthcare providers should advise patients on strategies to ensure medication adherence and continuity. Plans should be in place and ample supplies should be available to address any potential shortages or needs for rescue therapies.
If feasible, providers might consider writing 90-day rather than 30-day supplies of medications.
COVID-19 Vaccine Information
Monitoring Drug Shortages
- AES Clinical Corner: Paxlovid™, AES, February 25, 2022
- Paxlovid™ Information from FDA and Guidance for AES Members, AES, February 1, 2022
- Managing Patients with Epilepsy during COVID-19 - Pharmacotherapy-related Recommendations, AES, April 9, 2020
- Effective Engagement of Pharmacists During COVID-19 and Beyond, AES, April 9, 2020
- A Summary of Antiseizure Medications Available in the United States: 2020 Update, Tabular PDF summary of the most commonly used ASMs available for prescription in the United States. Updates and replaces the 2018 version.
- AES Comments on Therapeutic Substitution of Medications, April 3, 2020 [PDF]
- Substitution of different formulations of antiepileptic drugs for the treatment of epilepsy; a 2016 AES Position Statement
- Use of Generic AEDs: Free AES webinar (recorded in 2016, renewed in 2020); enduring material: 0.5 AMA PRA Category 1 Credits™ ; results of three well-designed, prospective studies on generic AED substitutions and clinical strategies for patients regarding generic AED substitution
Changes in Prescription Guidance
DEA: Temporary flexibility to prescribe buprenorphine for the treatment of opioid use disorder based on an evaluation via telephone